<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Stock Blog Hub &#187; SPPI</title>
	<atom:link href="http://www.stockbloghub.com/tag/sppi/feed" rel="self" type="application/rss+xml" />
	<link>http://www.stockbloghub.com</link>
	<description>Start Your Investing Research Here!</description>
	<lastBuildDate>Thu, 24 May 2012 23:16:35 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.2</generator>
		<item>
		<title>(SPPI) Spectrum Pharmaceuticals to Continue Cancer Study</title>
		<link>http://www.stockbloghub.com/2011/04/08/sppi-spectrum-pharmaceuticals-to-continue-cancer-study/70649</link>
		<comments>http://www.stockbloghub.com/2011/04/08/sppi-spectrum-pharmaceuticals-to-continue-cancer-study/70649#comments</comments>
		<pubDate>Fri, 08 Apr 2011 17:19:50 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Allos Therapeutics Inc.]]></category>
		<category><![CDATA[ALTH]]></category>
		<category><![CDATA[DMC]]></category>
		<category><![CDATA[Document Security Systems Inc]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>
		<category><![CDATA[SPA]]></category>
		<category><![CDATA[Sparton Corporation]]></category>
		<category><![CDATA[Spectrum Pharmaceuticals Inc.]]></category>
		<category><![CDATA[SPPI]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=70649</guid>
		<description><![CDATA[Recently, Spectrum Pharmaceuticals Inc. (SPPI) announced that it will continue evaluating its cancer candidate belinostat based on the recommendation of the independent Data Monitoring Committee (DMC). Spectrum Pharma is currently studying belinostat for treating patients suffering from relapsed or refractory peripheral T-Cell lymphoma (PTCL) in a phase II pivotal trial (BELIEF). Spectrum Pharma is evaluating belinostat as a monotherapy in the study. The committee conducted a safety and futility analysis of the interim data from the study before recommending its continuation until 100 evaluable subjects are enrolled. Spectrum Pharma is conducting the study under a Special Protocol Assessment (SPA) with the US Food and Drug Administration (FDA). Spectrum Pharma intends to seek approval of belinostat from the FDA in 2011/2012. We believe that if belinostat is successfully developed and commercialized ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/04/08/sppi-spectrum-pharmaceuticals-to-continue-cancer-study/70649/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(SPPI) Spectrum Pharmaceuticals Earnings Beat Expectations by a Penny</title>
		<link>http://www.stockbloghub.com/2010/04/07/sppi-spectrum-pharmaceuticals-earnings-beat-expectations-by-a-penny/33041</link>
		<comments>http://www.stockbloghub.com/2010/04/07/sppi-spectrum-pharmaceuticals-earnings-beat-expectations-by-a-penny/33041#comments</comments>
		<pubDate>Wed, 07 Apr 2010 23:00:27 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AGN]]></category>
		<category><![CDATA[Allergan Inc.]]></category>
		<category><![CDATA[Spectrum Pharmaceuticals]]></category>
		<category><![CDATA[SPPI]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=33041</guid>
		<description><![CDATA[Spectrum Pharmaceuticals (SPPI) reported fourth quarter earnings per share of 20 cents. The company posted a loss of 28 cents in the prior-year quarter. The swing from loss to profit was possible due to an accounting restatement made by the company to reclassify common stock warrants from equity to liability, resulting in an income of $19.8 million. Excluding the impact of the account restatement, Spectrum reported a loss of 19 cents compared to the Zacks Consensus Estimate of a loss of 20 cents. For 2009, the company reported a loss per share of 48 cents compared to a loss of 45 cents in 2008. During the fourth quarter and full year, Spectrum reported revenues of $8.6 million (year-over-year growth of 7.1%) and $38.02 million (a 32.5% growth), respectively. Spectrum has ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/04/07/sppi-spectrum-pharmaceuticals-earnings-beat-expectations-by-a-penny/33041/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(SPPI) Spectrum Pharmaceuticals is Denied Approval from US Food and Drug Administration</title>
		<link>http://www.stockbloghub.com/2009/10/14/sppi-spectrum-pharmaceuticals-is-denied-approval-from-us-food-and-drug-administration/17577</link>
		<comments>http://www.stockbloghub.com/2009/10/14/sppi-spectrum-pharmaceuticals-is-denied-approval-from-us-food-and-drug-administration/17577#comments</comments>
		<pubDate>Wed, 14 Oct 2009 16:42:25 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Charles River Laboratories International Inc]]></category>
		<category><![CDATA[CRL]]></category>
		<category><![CDATA[Spectrum Pharmaceuticals]]></category>
		<category><![CDATA[SPPI]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=17577</guid>
		<description><![CDATA[In a major disappointment for Spectrum Pharmaceuticals (SPPI), the US Food and Drug Administration (FDA) last week refused to approve the company’s supplemental New Drug Application (sNDA) for Fusilev (levoleucovorin) in its current form. The company was seeking approval for the treatment of patients with advanced metastatic colorectal cancer. Following the news, the shares plummeted 18% on Friday. Spectrum received a Complete Response Letter (CRL) from the FDA, in which the agency stated that the Fusilev data did not confirm the drug’s non-inferiority to leucovorin. Spectrum Pharmaceuticals plans to request a meeting with the agency to discuss the future course of action. The drug is currently approved by the FDA as a treatment option after high dose of methotrexate therapy in patients with osteosarcoma, a type of bone cancer. Earlier ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/10/14/sppi-spectrum-pharmaceuticals-is-denied-approval-from-us-food-and-drug-administration/17577/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(TRBN) Trubion Pharmaceuticals &amp; Facet Biotech to Jointly Develop and Market Leukemia Drug</title>
		<link>http://www.stockbloghub.com/2009/08/31/trbn-trubion-pharmaceuticals-facet-biotech-to-jointly-develop-and-market-leukemia-drug/13953</link>
		<comments>http://www.stockbloghub.com/2009/08/31/trbn-trubion-pharmaceuticals-facet-biotech-to-jointly-develop-and-market-leukemia-drug/13953#comments</comments>
		<pubDate>Mon, 31 Aug 2009 21:08:39 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Incorporated]]></category>
		<category><![CDATA[GENZ]]></category>
		<category><![CDATA[Genzyme Corporation]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[Spectrum Pharmaceuticals]]></category>
		<category><![CDATA[SPPI]]></category>
		<category><![CDATA[TRBN]]></category>
		<category><![CDATA[Trubion Pharmaceuticals Inc]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=13953</guid>
		<description><![CDATA[On Friday, Trubion Pharmaceuticals, Inc. (TRBN) agreed to jointly develop and commercialize TRU-016 globally with Facet Biotech Corp. (FACT).  TRU-016 is undergoing early-stage studies for chronic lymphocytic leukemia (CLL). The deal requires Facet to make a $20 million upfront payment to Trubion coupled with an additional $176.5 million on the achievement of certain milestones. Further, Facet has agreed to buy 2.24 million shares of newly issued Trubion common stock for $10 million. The companies have agreed to contribute equally towards costs related to development, commercialization and promotional activities. All global operating profits will be shared equally. The TRU-016 program is focused on the development of a novel CD37-targeted therapy for B-cell malignancies, such as Non-Hodgkin&#8217;s lymphoma (NHL) and CLL. CD37 is a clinically validated target for the treatment of B-cell ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/08/31/trbn-trubion-pharmaceuticals-facet-biotech-to-jointly-develop-and-market-leukemia-drug/13953/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

